Psoriasis Hastalarında Biyolojik Tedavinin Sistemik İnflamatuvar Belirteçler ve Plateletcrit Üzerine Etkisi

Amaç: Psoriasis keratinositlerin anormal proliferasyonu ve inflamatuvar hücre infiltrasyonu ile karakterize kronik inflamatuvar bir deri hastalığıdır. İnflamatuvar hücre ve sitokinler hastaların dokuları ile birlikte periferal kanda da tespit edilmektedir. Bugüne kadar psoriasis vulgariste pek çok inflamatuvar belirteç bildirilmiştir. Çalışmamızın amacı psoriasisli hastalarda biyolojik tedavi öncesi ve sonrası nötrofil/lenfosit oranı (NLO), lenfosit/monosit (LMO), platelet/lenfosit oranı (PLO), RDW/platelet (RPO) gibi sistemik inflamatuvar belirteçler ile plateletcrit (PCT)' nin değişimini araştırmaktır. Yöntemler: Biyolojik ajanlar ile tedavi edilmiş 42 psoriasis vulgaris hastası geriye dönük olarak değerlendirilmiştir. Hastaların demografik bilgileri, klinik verileri ve tam kan sayımı biyolojik tedavinin başlangıcından önce ve tedavi sonrası 3. ayda değerlendirilmiştir. Bulgular: Sedimentasyon, C-reaktif protein (CRP), nötrofil, trombosit, PCT, RDW, NLO ve PLO değerleri tedavi sonrası tedavi öncesi döneme göre istatistiksel anlamlı olarak azalmıştır (p0.05). Sonuç: NLO, PLO ve PCT psoriasis vulgaris hastalarının biyolojik ajan ile tedavi etkinliğinin değerlendirilmesinde bir belirteç olarak kullanılabilirler.

ÖZGÜN MAKALE/ORIGINAL ARTICLE

Objectives: Psoriasis is a chronic inflammatory skin disease characterized by abnormal proliferation of keratinocytes and inflammatory cell infiltration. Circulating inflammatory markers are increased in patients with psoriasis. The objective of this study is to assess neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), RDW to platelet ratio (RPR) and plateletcrit (PCT) as inflammatory markers in patients with psoriasis whom treated with biological agents. Methods: Forty-two patients with psoriasis vulgaris whom treated with biological agents were evaluated retrospectively. Information about demographics, clinics, and complete blood count of the patients before initiation and after 3 months of biological treatment were collected. Results: Erythrocyte sedimantation rate (ESR), C-reactive protein (CRP), neutrophil, platelet, PCT, RDW, NLR, and PLR were significantly reduced in the posttreatment results compared with the pretreatment results (p<0,05). Also, there were no statistically significant difference in terms of MPV, PDW, LMR, and RPR results (p>0,05). Conclusion: NLR, PLR and PCT may be used as a marker to evaluate biological agent treatment efficacy on psoriasis vulgaris patients.

PDF

___

1. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;94:302-9.

2. Hatipoğlu H, Erkal S, Türkmen S, ve ark. Enfeksiyon Hastalıklarının Tanısında Laboratuvar Bulguları. JOPP Derg, 2011;3:5-11.

3. Bugada D, Allegri M, Lavand'homme P, et al. Inflammationbased scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients. Biomed Res Int. 2014;2014:142425.

4. Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammationbased prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2012;7:587-94.

5. Yamagishi T, Fujimoto N, Nishi H, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma. Lung Cancer. 2015;90:111-7.

6. Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013;72:104-10.

7. Kim DS, Shin D, Jee H, et al. Red blood cell distribution width is increased in patients with psoriasis vulgaris: A retrospective study on 261 patients. J Dermatol. 2015;42:567-71.

8. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a populationbased study. Arch Dermatol. 2005;141:1537-41.

9. Yamanaka K, Umezawa Y, Yamagiwa A, et al. Biologic therapy improves psoriasis by decreasing the activity of monocytes and neutrophils. J Dermatol. 2014;41:679-85.

10. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013;11:88.

11. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137:19-27.

12. Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169:266-82.

13. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 2004;150:917-28.

14. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNFalpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005:273-9.

15. Boehncke WH. Perspective: Don't be superficial. Nature. 2012;492:55.

16. İlhan M, İlhan G, Gök AF, et al. Evaluation of neutrophillymphocyte ratio, platelet-lymphocyte ratio and red blood cell distribution width-platelet ratio as early predictor of acute pancreatitis in pregnancy. J Matern Fetal Neonatal Med. 2016;29:1476-80.

17. Balta S, Demirkol S, Unlu M, et al. Neutrophil to lymphocyte ratio may be predict of mortality in all conditions. Br J Cancer. 2013;109:3125-6.

18. Imtiaz F, Shafique K, Mirza SS, et al. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med. 2012;5:2.

19. Ataseven A, Bilgin AU, Kurtipek GS. The importance of neutrophil lymphocyte ratio in patients with psoriasis. Mater Sociomed. 2014;26:231-3.

20. Orem A, Değer O, Cimşit G, Bahadir S. Plasma polymorphonuclear leukocyte elastase levels and its relation to disease activity in psoriasis. Clin Chim Acta. 1997;264:49-56.

21. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102:5-14.

22. Demir M. The relationship between neutrophil lymphocyte ratio and non-dipper hypertension. Clin Exp Hypertens. 2013;35:570-3.

23. Boyraz I, Koç B, Boyacı A, et al. Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spondylitis that are treating with anti-TNF. Int J Clin Exp Med. 2014;7:2912-5.

24. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102:653-7.

25. Azab B, Jaglall N, Atallah JP, et al. Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology. 2011;11:445-52.

26. Torun S, Tunc BD, Suvak B, et al. Assessment of neutrophillymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity. Clin Res Hepatol Gastroenterol. 2012;36:491-7.

27. Duffy BK, Gurm HS, Rajagopal V, et al. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2006;97:993-6.

28. Azab B, Zaher M, Weiserbs KF, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and longterm mortality after non-ST-elevation myocardial infarction. Am J Cardiol. 2010;106:470-76.

29. Park JJ, Jang HJ, Oh IY, et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013;111:636-42.

30. Erturk M, Surgit O, Yalcin AA, et al. The evaluation of relationship between neutrophil-to-lymphocyte ratio and slow coronary flow. Dicle Med J 2013;40:537-42.

31. Smith RA, Bosonnet L, Ghaneh P, et al. The plateletlymphocyte ratio improves the predictive value of serum CA19- 9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery. 2008;143:658-66.

32. Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program. 2011;2011:51-61.

33. Azab B, Shah N, Akerman M, McGinn JT Jr. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012;34:326-34.

34. Kilic E, Rezvani A, Toprak AE, et al. Evaluation of Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Rheumatoid Arthritis. Dicle Med J 2016;43:241-7.

35. Gunbatar H, Ekin S, Sunnetcioglu A, et al. The relationship between neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio in patients with obstructive sleep apnea syndrome. Dicle Med J 2015;42:289-93.

36. Kim DS, Shin D, Lee MS, et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016;43:305-10.

37. Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet function in cutaneous diseases. Platelets. 2008; 19: 317-21.

38. Kim DS, Lee J, Kim SH, et al. Mean platelet volume is elevated in patients with psoriasis vulgaris. Yonsei Med J. 2015;56:712-8.

39. Oylumlu M, Oylumlu M, Yuksel M, et al. The usefulness of plateletcrit to predict cardiac syndrome X in patients with normal coronary angiogram. Postepy Kardiol Interwencyjnej. 2015;11:197-201.

40. Aynıoglu O, Isık H, Sahbaz A, et al. Can Plateletcrit be a Marker for Recurrent Pregnancy Loss? Clin Appl Thromb Hemost. 2016;22:447-52.

41. Yurtdaş M, Yaylali YT, Kaya Y, et al. Neutrophil-tolymphocyte ratio may predict subclinical atherosclerosis in patients with psoriasis. Echocardiography. 2014;31:1095-104.

42. Balta I, Balta S, Demirkol S, et al. Neutrophil-to-lymphocyte ratio may predict subclinical atherosclerosis in patient with psoriasis. Echocardiography. 2014;31:1166-7.

43. Balta I, Balta S, Demirkol S, et al. Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology. 2014;65:74-78.

44. Nguyen T, Wu JJ. Relationship between tumor necrosis factor-? inhibitors and cardiovascular disease in psoriasis: a review. Perm J. 2014;18:49-54.

45. Ünal M, Küçük A, Ünal GÜ, et al. Psoriasiste trombosit hacmi, nötrofil/lenfosit-trombosit/lenfosit oranı. Türkderm 2015;49:112-6.